Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8270922 | 0.83 | FFAR1 (0.40) | FFAR1KCNH2GRIN2BDAORIPK1 | |
| SCHEMBL12126170 | 0.80 | FFAR1 (0.44) | FFAR1KCNH2GRIN2BDAOMPO | |
| SCHEMBL12126268 | 0.77 | FFAR1 (0.42) | FFAR1KCNH2GRIN2BDAOMPO | |
| SCHEMBL2608838 | 0.76 | FFAR1 (0.39) | FFAR1KCNH2GRIN2BDAOMPO | |
| SCHEMBL13402954 | 0.75 | MAPK1 (0.46) | MEN1KMT2A | |
| SCHEMBL25038987 | 0.71 | FFAR1 (0.38) | FFAR1KCNH2GRIN2BDAOMPO | |
| SCHEMBL324196 | 0.70 | FFAR1 (0.40) | FFAR1KCNH2GRIN2BDAOMPO | |
| SCHEMBL12126344 | 0.69 | FFAR1 (0.44) | FFAR1KCNH2MEN1KMT2ADAO | |
| SCHEMBL28311316 | 0.69 | GLS (0.53) | MEN1KMT2A | |
| SCHEMBL24933018 | 0.69 | FFAR1 (0.53) | FFAR1KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | FFAR1 1580/4885KCNH2 2028/4885MEN1 4094/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | FFAR1 501/4885KCNH2 2809/4885MEN1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.